Aclaris Therapeutics ACRS Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 73.3%-11.8pp | 85.1%-4.0pp | 89%+2.6pp | 86.5%+56.2pp | |
| Operating margin | -975.9%-218pp | -758.1%-447pp | -311.6%-9.5pp | -302%+1,025pp | |
| Net margin | -829.6%-124pp | -705.4%-422pp | -283.1%+9.0pp | -292.1%+1,052pp | |
| EBITDA margin | -970.1%-216pp | -753.8%-445pp | -308.8%-9.5pp | -299.3%+1,014pp | |
| Free cash flow margin | -603.4%— | —— | -254.8%-25.7pp | -229.1%— | |
| Returns | |||||
| Return on equity | -50.2%+34.3pp | -84.5%-34.6pp | -49.9%-5.9pp | -44%+33.3pp | |
| Return on assets | -34.1%+29.1pp | -63.2%-24.1pp | -39.2%-4.8pp | -34.4%+22.1pp | |
| Return on invested capital | -69.8%+41.8pp | -111.6%-40.9pp | -70.7%-15.8pp | -54.9%+33.7pp | |
| Efficiency | |||||
| Asset turnover | 0×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×+0.1× | |
| Liquidity | |||||
| Current ratio | 3.4×-0.6× | 4×-0.2× | 4.2×-6.4× | 10.6×+1.6× | |
| Quick ratio | 3.4×-0.6× | 4×-0.2× | 4.2×-6.4× | 10.6×+1.6× | |
| Cash ratio | 0.7×-0.1× | 0.8×-0.5× | 1.3×-0.8× | 2.1×+0.9× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | |||||
| Book value per share | $0.84-58.2% | $2.01-10.6% | $2.25-25.7% | $3.03-12.9% | |
| Valuation | |||||
| Market capitalization | $685.75M+337% | $265.41M+257% | $74.38M-92.9% | $1.05B+18.0% | |
| Enterprise value | $659.07M+410% | $243.43M+541% | $38M-96.2% | $1.01B+16.3% | |
| Price / sales | 82×+73.1× | 14.2×+11.8× | 2.4×-32.9× | 35.3×-96.4× | |
| Price / book | 4.8×+3.7× | 1.7×+1.2× | 0.5×-4.8× | 5.3×+0.8× | |
| EV / sales | 78.8×+71.5× | 13×+11.8× | 1.2×-32.6× | 33.9×-94.2× | |
| Free cash flow yield | -7.6%— | —— | -107.1%-101pp | -6.5%— | |
| Earnings yield | -10.2%+72.8pp | -49.8%+69.2pp | -119%-111pp | -8.3%+1.9pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Aclaris Therapeutics's profit margins?
- Aclaris Therapeutics (ACRS) runs a 76.3% gross margin and a -961.9% operating margin, with a -832.6% net margin.
- Where do Aclaris Therapeutics's ratios come from?
- Every ratio is computed from Aclaris Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
